No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Saintno Pharmaceutical-B has completed the issuance of 17.5277 million shares.
Shengnuo Pharmaceutical-B (02257) announced that on December 2, 2024, it will issue 17.5277 million shares after completing the subscription of new shares according to the general authorization based on the subscription agreement dated October 2, 2024.
Express News | Sirnaomics Ltd - Got Letter of Resignation From Shing Mo Han, Yvonne to Resign as Chairperson of Board
Express News | Sirnaomics Ltd - Yang Lu Re-Designated From an Executive Director to a Non-Executive Director
San Nova Pharmaceutical-B (02257.HK): Lu Yang and Sheng Muxian resign as members of the investigation committee.
GraceAlliance October 29th, Shengnuo Pharmaceuticals-B (02257.HK) announced that the board of directors has established an investigation committee, chaired by the chairman of the board and executive director Lu Yang, along with all independent non-executive directors, namely Chang Hai, Huang Mengying, and Shengmuxian, to investigate the incident that the issuer of the private placement bonds invested by the fund may default, expecting a significant adverse change in the net asset value of the fund. The board of directors has received notifications from Lu Yang and Shengmuxian voluntarily resigning as members of the investigation committee to devote more time to their respective duties prior to being appointed as members of the investigation committee, effective October 29, 2024.
Press Release: Sirnaomics Promotes Francois Lebel, M.D. to Chief Medical Officer
